Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Front-Runners Emerge In Race For EMA

Executive Summary

Five countries appear to be ahead in the battle to host the European Medicines Agency after Brexit, judging by the results of a European Commission assessment and an EMA staff survey, although much horse-trading among member states is expected before the winner is announced in November.

You may also be interested in...



EMA Discloses Staff’s Preferred Host Cities, Amid Fears Relocation Could Batter Its Budget

The EMA has published its analysis of the 19 bids to host the agency post-Brexit, which confirms reports that five cities – Amsterdam, Barcelona, Copenhagen, Milan and Vienna – would bring the best result in terms of retaining staff when it relocates. The agency has expressed concern that low retention rates could hit operations and result in lower fee income, requiring an injection of cash from the EU budget.

Spain's Oryzon Moves To Madrid From Barcelona As Catalan Crisis Deepens

As tensions continue to rise in Catalonia in the aftermath of the illegal independence referendum, one of Spain's most high-profile biotechs has decided to move its headquarters to Madrid, leaving observers to wonder if other companies, including multinationals, will follow.

EMA Paints Nightmare Scenario Of EU System ‘Unraveling’ If Relocation Goes Wrong

The European Medicines Agency says it could lose more than 70% of its staff if it moves to one of the cities least favored by current employees. In the worst-case scenario, the EMA says it would be unable to operate and that the regulatory system would “unravel.”

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS121681

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel